Muscle relaxants' "OTCness" to be considered by NDAC at March 27-28 meeting.
This article was originally published in The Tan Sheet
Executive Summary
MUSCLE RELAXANTS' POTENTIAL "OTCness" TO BE ADDRESSED BY NDAC on March 28 during a joint meeting with FDA's Arthritis Advisory Committee. FDA is interested in committee discussion on appropriate OTC indications for muscle relaxants, doses and directions for use, safety profiles, abuse potential and pharmacokinetic information.